Read a refresh of GI cancer FDA news from August 2026, including the approval of a RAS(ON) inhibitor in metastatic pancreatic cancer.
Commentary|Articles|January 15, 2026
Targeted Strategies, Systemic Therapies, and AI Advances Emerge as Central Themes From ASCO GI 2026
Author(s)Courtney Flaherty
Fact checked by: Chris Ryan
Experts reflect on pivotal data from the 2026 Gastrointestinal Cancers Symposium that are set to change practice in HCC, CRC, and other GI cancers.
Advertisement
Advertisement
The
Related to this article
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Monthly etentamig significantly improved response and PFS over standard available therapies in the phase 3 CERVINO trial, with low rates of high-grade CRS.
Results from an early-stage clinical trial found encouraging outcomes in newly diagnosed pancreatic cancer that had spread to distant organs.
Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across two cevostamab dose levels, supporting selection of a recommended phase 3 regimen.
A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.
Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.
Advertisement
Advertisement